Teva Pharmaceutical enters into collaborative development agreement for Xenon Pharmaceuticals pain drug

Posted on December 11th, by Michael Shapiro-Barr

Teva Pharmaceutical Industries Ltd has entered into a collaborative agreement with Xenon Pharmaceuticals Inc. for worldwide license for XEN402. XEN402 is currently in clinical development for a variety of painful disorders. As a part of the agreement, Teva will pay Xenon an upfront fee of $41 million, in addition to paying development, regulatory, and sales-based milestones totaling $335 million.

Comments are closed.

From the Blog

Where to Spend Your Healthcare Investment Dollars

In a blog entry written over the summer, I expressed the view that the next 5-10 years will present tremendous transactional opportunities in the life...

Second Circuit Rejects Government’s Off-Label Enforcement Approach

Last week’s decision in the off-label promotion case, United States v. Caronia, No. 09-5006-cr (2d Cir. Dec. 3, 2012), is an important blow to...

Massachusetts Refines Its Sunshine Law; Final Federal Sunshine Regulations Moving Ahead

The relationship between health care providers and drug and device manufacturers has been a focus of lawmakers at both the federal and state level. ...

Close for now.

Never show again.

Subscribe by Email for New Blog Posts

Teva Pharmaceutical enters into collaborative development agreement for Xenon Pharmaceuticals pain drug

Recent Posts

Subscribe via Email

Blogroll

From the Blog

Where to Spend Your Healthcare Investment Dollars

Second Circuit Rejects Government’s Off-Label Enforcement Approach

Massachusetts Refines Its Sunshine Law; Final Federal Sunshine Regulations Moving Ahead